Genmab A/S (GMAB) vs Veradermics (MANE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Genmab A/S is the larger company by market cap ($22.54 billion vs $4.64 billion), about 4.9 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GMAB | MANE |
|---|---|---|
| Share price | $36.65 | $110.95 |
| Market cap | $22.54B | $4.64B |
| 1-day change | -3.04% | +1.83% |
| YTD return | +18.99% | — |
| 1-year return | +12.29% | — |
| 5-year return | -17.51% | — |
| P/E ratio (TTM) | 28.86 | — |
| Forward P/E | 24.03 | — |
| EPS (TTM) | $1.27 | $-4.24 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.72B | — |
| Revenue growth (YoY) | +19.19% | — |
| Net income (latest FY) | $963.00M | $-70.00M |
| Gross margin | 93.60% | — |
| Operating margin | 28.63% | — |
| Net margin | 25.89% | — |
| 52-week high | $40.17 | $131.24 |
| 52-week low | $23.62 | $32.00 |
| Distance from 52-week high | -8.76% | -15.46% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +17.93% | +47.36% |
| Average volume | 2.78M | 730.99K |
| Shares outstanding | 614.90M | 41.78M |
| Employees | 3,119 | 37 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Genmab A/S is about 4.9 times larger than Veradermics by market value ($22.54B vs $4.64B).
About Genmab A/S
GMAB stock →Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
Health Care · Biotechnology: Pharmaceutical Preparations · 3,119 employees
About Veradermics
MANE stock →Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children.
Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees
GMAB vs MANE FAQ
Which is bigger, Genmab A/S or Veradermics?
Genmab A/S (GMAB) is larger, with a market capitalization of $22.54B compared with $4.64B for Veradermics (MANE).
Are Genmab A/S and Veradermics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.